Stratification of Outcomes for Lymphoma In Dogs with Relapsed Lymphoma (SOLID-Relapse)
OpenSummary of Study:
The Stratification of Outcomes for Lymphoma In Dogs with Relapsed Lymphoma (SOLID-Relapse) study is a clinical trial focused on the follow- up of dogs previously enrolled in Ethos-SOLID. This population of relapsed patients will add the perspective of longitudinal analysis and provide a unique opportunity to study the role of functional precision medicine in treatment of relapsed lymphoma. The goal of the study is to identify evolutionary shifts in dogs with multicentric lymphoma from time of diagnosis to disease relapse and evaluate the impact of functional precision medicine.
Inclusion Criteria
Dogs must have:
- Previous Enrollment into the Ethos SOLID study
- Completion of at least one 4-week cycle of CHOP
- Cytologically confirmed relapsed peripheral nodal lymphoma amenable to tissue biopsy
- Confirmation of lymphoma by a clinical pathologist is encourage but not required.
- Informed consent signed by owner
- No chemotherapy or steroids for 7 days prior to enrollment.
Study Procedures:
About the Ethos-SOLID Study
- Dogs diagnosed with multicentric nodal lymphoma and previously enrolled in Ethos – SOLID will be eligible for this study. Screening includes blood work, chest x-rays, and lymph node biopsy.
- Eligible dogs will be randomized into 2 groups and receive specific treatment under the care of an Ethos Veterinary Health Oncologist.
- A key part of the study involves collecting blood and tissue samples to study gene variants and biomarkers. These insights aim to improve prognosis and develop better treatment options for canine lymphoma.
What to Expect:
- Blood samples will be taken before treatment begins, and at various points during and after chemotherapy.
- Only one lymph node biopsy (during initial screening) is required.
- Treatment and monitoring will continue until disease progression or Serious Adverse Event.
- After progression, dogs will be removed from the study but may continue care with their Oncologist.
Financial incentives:
Study Financial Support
The study covers:
- Full cost of screening (bloodwork, urinalysis, chest x-rays, lymph node biopsy, flow cytometry)
- Routine bloodwork and urinalysis at set points during the study
- Up to $4500 in Compensation for chemotherapy, exams, diagnostics, and medications for chemo-related side effects
Note: This compensation would be for CHOP and cover either precision medicine or clinicians choice in terms of treatment.
Interested?
Enroll or request more information below